[go: up one dir, main page]

CY1108486T1 - Μορφες δοσολογιας αζιθρομυκινης με μειωμενες παρενεργειες - Google Patents

Μορφες δοσολογιας αζιθρομυκινης με μειωμενες παρενεργειες

Info

Publication number
CY1108486T1
CY1108486T1 CY20081101264T CY081101264T CY1108486T1 CY 1108486 T1 CY1108486 T1 CY 1108486T1 CY 20081101264 T CY20081101264 T CY 20081101264T CY 081101264 T CY081101264 T CY 081101264T CY 1108486 T1 CY1108486 T1 CY 1108486T1
Authority
CY
Cyprus
Prior art keywords
azithromycin
glyceryl
effective amount
agent
alkalizing agent
Prior art date
Application number
CY20081101264T
Other languages
English (en)
Inventor
Leah Elizabeth Appel
Marshall David Crew
Dwayne Thomas Friesen
Timothy Arthur Hagen
Scott Max Herbig
Julian Belknap Lo
David Keith Lyon
Scott Baldwin Mccray
Avinash Govind Thombre
James Blair West
Original Assignee
Pfizer Products Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34468055&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1108486(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Products Incorporated filed Critical Pfizer Products Incorporated
Publication of CY1108486T1 publication Critical patent/CY1108486T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

Μία μορφή δοσολογίας δια του στόματος περιλαμβάνουσα αζιθρομυκίνη και μία αποτελεσματική ποσότητα ενός παράγοντα αλκαλοποιήσεως. Κατά προτίμηση, η εν λόγω μορφή δοσολογίας δια του στόματος περιλαμβάνει μία αποτελεσματική ποσότητα ενός παράγοντα αλκαλοποιήσεως και μία πολυσωματιδιακή αζιθρομυκίνη όπου τα εν λόγω πολυσωματίδια περιλαμβάνουν αζιθρομυκίνη, ένα μίγμα μονοβεχενικού γλυκερυλίου, διβεχενικού γλυκερυλίου και τριβεχενικού γλυκερυλίου και ένα πολοξαμερές. Τυπικά, η μορφή δοσολογίας δια του στόματος περιλαμβάνει οποιοδήποτε κατάλληλο μέσο χορηγήσεως δια του στόματος όπως κόνη για στοματικό εναιώρημα, ένα πακέτο ή φακελίσκο μοναδιαίας δόσεως, ένα δισκίο ή μία κάψουλα. Αποκαλύπτεται επί πλέον ένα στοματικό εναιώρημα περιλαμβάνον αζιθρομυκίνη, μία αποτελεσματική ποσότητα ενός παράγοντα αλκαλοποιήσεως και ένα όχημα. Κατά προτίμηση, η αζιθρομυκίνη είναι σε πολυσωματιδιακή μορφή όπου η εν λόγω πολυσωματιδιακή σύνθεση περιλαμβάνει αζιθρομυκίνη, ένα μίγμα μονοβεχενικού γλυκερυλίου, διβεχενικού γλυκερυλίου και τριβεχενικού γλυκερυλίου και ένα πολοξαμερές. Αποκαλύπτεται επίσης μία μέθοδος μειώσεως των γαστρεντερικών παρενεργειών που συνδέονται με τη χορήγηση αζιθρομυκίνης σε ένα θηλαστικό, περιλαμβάνουσα τη γειτονική χορήγηση αζιθρομυκίνης και μίας αποτελεσματικής ποσότητας ενός παράγοντα αλκαλοποιήσεως στο εν λόγω θηλαστικό όπου η συχνότητα των γαστρεντερικών παρενεργειών είναι χαμηλότερη από εκείνη που παρουσιάζεται δια χορηγήσεως μίας ίσης δόσεως αζιθρομυκίνης χωρίς τον εν λόγω παράγοντα αλκαλοποιήσεως. Αποκαλύπτεται περαιτέρω μία μέθοδος αγωγής μίας βακτηριακής ή πρωτοζωικής λοιμώξεως
CY20081101264T 2003-12-04 2008-11-06 Μορφες δοσολογιας αζιθρομυκινης με μειωμενες παρενεργειες CY1108486T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52708403P 2003-12-04 2003-12-04
US10/763,340 US6984403B2 (en) 2003-12-04 2004-01-23 Azithromycin dosage forms with reduced side effects
EP04252643A EP1537859B1 (en) 2003-12-04 2004-05-06 Azithromycin dosage forms with reduced side effects

Publications (1)

Publication Number Publication Date
CY1108486T1 true CY1108486T1 (el) 2014-04-09

Family

ID=34468055

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081101264T CY1108486T1 (el) 2003-12-04 2008-11-06 Μορφες δοσολογιας αζιθρομυκινης με μειωμενες παρενεργειες

Country Status (36)

Country Link
US (4) US6984403B2 (el)
EP (1) EP1537859B1 (el)
JP (2) JP4602711B2 (el)
KR (1) KR100906290B1 (el)
AR (1) AR045630A1 (el)
AT (1) ATE407663T1 (el)
BR (1) BRPI0403935B8 (el)
CA (1) CA2467611C (el)
CL (1) CL2004001501A1 (el)
CR (1) CR7500A (el)
CY (1) CY1108486T1 (el)
DE (1) DE602004016444D1 (el)
DK (1) DK1537859T3 (el)
DO (1) DOP2004000994A (el)
EA (1) EA010110B1 (el)
ES (1) ES2312929T3 (el)
GE (1) GEP20074056B (el)
HK (1) HK1080367B (el)
HR (1) HRP20040865A2 (el)
IL (1) IL164165A (el)
IS (1) IS2672B (el)
MA (1) MA27848A1 (el)
MX (1) MXPA04009424A (el)
NL (1) NL1026315C2 (el)
NO (1) NO20043903L (el)
NZ (1) NZ535464A (el)
OA (1) OA12858A (el)
PA (1) PA8611501A1 (el)
PE (1) PE20050573A1 (el)
PL (2) PL1537859T3 (el)
PT (1) PT1537859E (el)
RS (1) RS84704A (el)
SI (1) SI1537859T1 (el)
TW (1) TWI351969B (el)
UY (1) UY28509A1 (el)
WO (1) WO2005053650A1 (el)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2130311C1 (ru) † 1994-05-06 1999-05-20 Пфайзер Инк. Лекарственные формы азитромицина с контролируемым высвобождением
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
SI1615646T2 (sl) * 2003-04-08 2022-11-30 Progenics Pharmaceuticals, Inc. Farmacevtske formulacije vsebujoče metilnatrekson
WO2005053652A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
AU2004294817B2 (en) * 2003-12-04 2007-01-25 Pfizer Products Inc. Method for making pharmaceutical multiparticulates
MXPA06011765A (es) * 2004-04-12 2006-12-15 Pfizer Prod Inc Farmacos de sabor enmascarado en multiparticulados que se rompen.
SI1765292T1 (en) 2004-06-12 2018-04-30 Collegium Pharmaceutical, Inc. Formulations of medicines to discourage abuse
EP1782816B1 (en) * 2004-07-02 2011-10-19 Wakamoto Pharmaceutical Co., Ltd. Water-based medicinal composition containing azithromycin and method of preparing the same
JP4713104B2 (ja) * 2004-08-04 2011-06-29 ファイザー株式会社 アジスロマイシン類を有効成分とする苦味が抑制された安定な組成物
US20060193908A1 (en) * 2004-11-09 2006-08-31 Burnside Beth A Extended release formulations of poorly soluble antibiotics
AU2006220682B2 (en) * 2005-03-07 2012-05-31 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US8524731B2 (en) * 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US20060252830A1 (en) * 2005-05-06 2006-11-09 Brandon Stephen F Method for the treatment of magnesium and potassium deficiencies
US20060252831A1 (en) * 2005-05-06 2006-11-09 Christopher Offen Method for the treatment of magnesium and potassium deficiencies
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) * 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
JP5252926B2 (ja) * 2005-12-22 2013-07-31 大塚製薬株式会社 薬物含有ワックスマトリックス粒子の製造方法、該方法に使用されるエクストルーダー、及びシロスタゾールを含有する徐放性製剤
CN101340882B (zh) * 2005-12-22 2015-02-11 大塚制药株式会社 含有药物的蜡基质粒子的制造方法、用于该方法的挤出机、及含有西洛他唑的缓释制剂
JP2009539866A (ja) * 2006-06-05 2009-11-19 オースペックス・ファーマシューティカルズ・インコーポレイテッド 置換エリスロマイシンアナログの調製および有用性
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
US11116728B2 (en) 2006-11-30 2021-09-14 Bend Research, Inc. Multiparticulates of spray-coated drug and polymer on a meltable core
WO2008065504A1 (en) * 2006-11-30 2008-06-05 Pfizer Products Inc. Multiparticulates of spray-coated drug and polymer on a meltable core
JP5162134B2 (ja) * 2007-01-22 2013-03-13 愛媛県 機能性材料の製造方法、機能性材料、シート状構造体、及び衛生製品
EP2144599B1 (en) * 2007-03-02 2010-08-04 Farnam Companies, Inc. Sustained release pellets comprising wax-like material
EP2134718A2 (en) * 2007-03-29 2009-12-23 Progenics Pharmaceuticals, Inc. Crystal forms of (r)-n-methylnaltrexone bromide and uses thereof
PT2139890E (pt) 2007-03-29 2014-09-03 Wyeth Llc Antagonistas do receptor opióide periférico e respectivas utilizações
CA2682125C (en) 2007-03-29 2015-06-16 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
DE102007026550A1 (de) * 2007-06-08 2008-12-11 Bayer Healthcare Ag Extrudate mit verbesserter Geschmacksmaskierung
DE102007034155A1 (de) * 2007-07-21 2009-01-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Vorrichtung mit mindestens einer Verpackungseinheit mit einem zur Radiofrequenz-Identifikation dienenden RFID-Chip und Verfahren dazu
EP2237684A2 (en) 2008-01-08 2010-10-13 Akthelia Pharmaceuticals Agonists for antimicrobial peptide systems
AU2008349873B2 (en) * 2008-02-06 2014-02-13 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2'-bis-methylnaltrexone
AU2009225434B2 (en) 2008-03-21 2014-05-22 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
WO2010011609A2 (en) * 2008-07-21 2010-01-28 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
US8106111B2 (en) 2009-05-15 2012-01-31 Eastman Chemical Company Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions
EP2314286A1 (de) * 2009-10-21 2011-04-27 Ratiopharm GmbH Schmelzgranuliertes Cinacalcet
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
WO2011125075A2 (en) 2010-04-08 2011-10-13 Fdc Limited A novel gastroretentive delivery of macrolide
KR101896732B1 (ko) 2011-02-11 2018-09-07 제트에스 파마, 인코포레이티드 고칼륨혈증의 치료를 위한 미세다공성 규산지르코늄
EP2714937B1 (en) 2011-06-03 2018-11-14 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
WO2013088274A1 (en) 2011-12-14 2013-06-20 Wockhardt Limited Anhydrous amorphous azithromycin composition free of azithromycin dihydrate
US9943637B2 (en) 2012-06-11 2018-04-17 ZS Pharma, Inc. Microporous zirconium silicate and its method of production
IN2015KN00201A (el) 2012-07-11 2015-06-12 Zs Pharma Inc
US10695365B2 (en) 2012-10-22 2020-06-30 ZS Pharma, Inc. Microporous zirconium silicate for the treatment of hyperkalemia
BR112015008962B1 (pt) 2012-10-22 2021-09-21 Zs Pharma, Inc Composição de silicato de zircônio para o tratamento de hipercalemia
BR112016013197A2 (pt) * 2013-12-10 2018-05-22 Zs Pharma Inc silicato de zircônio para tratar hipercalemia sem co-administração de lítio.
US10259791B2 (en) 2014-08-28 2019-04-16 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
JP6792546B2 (ja) * 2015-02-25 2020-11-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 キノリン誘導体の苦味抑制方法
JP2018511582A (ja) * 2015-03-10 2018-04-26 ルモス ファーマ， インコーポレイテッド シクロクレアチン微細懸濁物
US10286003B2 (en) 2015-06-10 2019-05-14 Piedmont Animal Health, Llc Injectable antibiotic formulations and use thereof
BR112017027227B1 (pt) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
US12220398B2 (en) 2015-08-20 2025-02-11 Eisai R&D Management Co., Ltd. Tumor therapeutic agent
HRP20220856T1 (hr) 2016-03-15 2022-10-14 Acer Therapeutics Inc. Pripravci ugodna okusa uključujući natrijev fenilbutirat i njihove uporabe
WO2017222575A1 (en) 2016-06-23 2017-12-28 Collegium Pharmaceutical, Inc. Process of making more stable abuse-deterrent oral formulations
JP7159174B2 (ja) * 2017-02-02 2022-10-24 マックマスター、ユニバーシティー 抗菌剤用増強剤としての重炭酸塩
SG11201910100PA (en) 2017-05-16 2019-11-28 Eisai R&D Man Co Ltd Treatment of hepatocellular carcinoma
CR20200419A (es) 2018-02-18 2020-10-23 G & G Biotechnology Ltd Implantes con adhesión mejorada a la cubierta
EP3829640A4 (en) 2018-08-01 2022-05-25 McMaster University Methods for inhibiting microbe growth
CN111643455A (zh) * 2020-06-22 2020-09-11 健民药业集团股份有限公司 一种阿奇霉素缓释干混悬剂及其制备方法
WO2022220669A1 (es) * 2021-04-16 2022-10-20 Garcia Perez Miguel Angel Combinación sólida oral para el tratamiento de infección por virus
CN114699386B (zh) * 2022-04-14 2023-05-23 深圳职业技术学院 阿奇霉素组合物及其制备方法

Family Cites Families (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6650A (en) * 1849-08-14 Edmund blunt
US25342A (en) * 1859-09-06 Justus k
US3590A (en) * 1844-05-17 Rule or measure
US14951A (en) * 1856-05-27 Boot-tree
US165563A (en) * 1875-07-13 Improvement in snow-plows
US190365A (en) * 1877-05-01 Improvement in running-gear for vehicles
US228357A (en) * 1880-06-01 Walter m
US26851A (en) * 1860-01-17 Improvement
US2955956A (en) * 1957-05-15 1960-10-11 Morton Salt Co Process and apparatus for coating granules
US4092089A (en) * 1974-04-06 1978-05-30 Bayer Aktiengesellschaft Apparatus for the preparation of melt-sprayed spherical phenacetin granules
US4086346A (en) * 1974-04-06 1978-04-25 Bayer Aktiengesellschaft Preparation of melt-sprayed spherical phenacetin granules
US4053264A (en) * 1976-01-30 1977-10-11 United Technologies Corporation Apparatus for making metal powder
US4293570A (en) * 1979-04-02 1981-10-06 Chimicasa Gmbh Process for the preparation of sweetener containing product
SI8110592A8 (en) * 1981-03-06 1996-06-30 Pliva Pharm & Chem Works Process for preparing of n-methyl-11-aza-10-deoxo-10-dihydroerythromycine a and derivatives thereof
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
KR920006865B1 (ko) * 1984-05-18 1992-08-21 워싱톤 유니버시티 테크놀러지 어소우시에이츠 인코오퍼레이티드 입자나 액적을 피복하는 방법과 장치
US4874611A (en) 1985-06-20 1989-10-17 The Dow Chemical Company Microencapsulated ant bait
US5019302A (en) * 1986-03-12 1991-05-28 Washington University Technology Associates, Inc. Method for granulation
US5100592A (en) * 1986-03-12 1992-03-31 Washington University Technology Associated, Inc. Method and apparatus for granulation and granulated product
US5456932A (en) 1987-04-20 1995-10-10 Fuisz Technologies Ltd. Method of converting a feedstock to a shearform product and product thereof
US5236734A (en) * 1987-04-20 1993-08-17 Fuisz Technologies Ltd. Method of preparing a proteinaceous food product containing a melt spun oleaginous matrix
US5387431A (en) * 1991-10-25 1995-02-07 Fuisz Technologies Ltd. Saccharide-based matrix
MX12213A (es) * 1987-07-09 1993-05-01 Pfizer Metodo de preparacion de dihidrato de azitromicina cristalino
WO1989002271A1 (en) 1987-09-10 1989-03-23 Pfizer Azithromycin and derivatives as antiprotozoal agents
HRP20020231A2 (en) * 2002-03-18 2003-12-31 Pliva D D ISOSTRUCTURAL PSEUDOPOLYMORPHS OF 9-DEOXO-9a-AZA-9a-METHYL-9a-HOMOERYTHROMYCIN A
DE3812567A1 (de) * 1988-04-15 1989-10-26 Basf Ag Verfahren zur herstellung pharmazeutischer mischungen
US5064650A (en) 1988-04-19 1991-11-12 Southwest Research Institute Controlled-release salt sensitive capsule for oral use and adhesive system
US5160743A (en) 1988-04-28 1992-11-03 Alza Corporation Annealed composition for pharmaceutically acceptable drug
US5024842A (en) * 1988-04-28 1991-06-18 Alza Corporation Annealed coats
US4931285A (en) * 1988-04-28 1990-06-05 Alza Corporation Aqueous based pharmaceutical coating composition for dosage forms
US5047244A (en) * 1988-06-03 1991-09-10 Watson Laboratories, Inc. Mucoadhesive carrier for delivery of therapeutical agent
US5169645A (en) 1989-10-31 1992-12-08 Duquesne University Of The Holy Ghost Directly compressible granules having improved flow properties
JPH03206039A (ja) * 1990-01-08 1991-09-09 Kyoto Yakuhin Kogyo Kk ニフェジピン持続性製剤
US5084287A (en) * 1990-03-15 1992-01-28 Warner-Lambert Company Pharmaceutically useful micropellets with a drug-coated core and controlled-release polymeric coat
US5213810A (en) * 1990-03-30 1993-05-25 American Cyanamid Company Stable compositions for parenteral administration and method of making same
EP0452862B1 (en) * 1990-04-18 1995-07-19 Asahi Kasei Kogyo Kabushiki Kaisha Spherical seed cores, spherical granules and process for production thereof
US5183690A (en) * 1990-06-25 1993-02-02 The United States Of America, As Represented By The Secretary Of Agriculture Starch encapsulation of biologically active agents by a continuous process
GB9014646D0 (en) 1990-07-02 1990-08-22 Courtaulds Coatings Holdings Coating compositions
US5194262A (en) * 1990-10-22 1993-03-16 Revlon Consumer Products Corporation Encapsulated antiperspirant salts and deodorant/antiperspirants
US5196199A (en) * 1990-12-14 1993-03-23 Fuisz Technologies Ltd. Hydrophilic form of perfluoro compounds and method of manufacture
US5292657A (en) * 1990-12-31 1994-03-08 Pioneer Hi-Bred International, Inc. Process for preparing rotary disc fatty acid microspheres of microorganisms
US5143662A (en) * 1991-02-12 1992-09-01 United States Surgical Corporation Process for preparing particles of bioabsorbable polymer
US5707546A (en) * 1991-06-17 1998-01-13 Rio Linda Chemical Co., Inc. Generation and storage of chlorine dioxide in a non-aqueous medium
US5405617A (en) * 1991-11-07 1995-04-11 Mcneil-Ppc, Inc. Aliphatic or fatty acid esters as a solventless carrier for pharmaceuticals
GB9201857D0 (en) * 1992-01-29 1992-03-18 Smithkline Beecham Plc Novel compound
JP3265680B2 (ja) * 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
DE4214272A1 (de) * 1992-05-04 1993-11-11 Nukem Gmbh Verfahren und Vorrichtung zur Herstellung von Mikrokugeln
CA2095776C (en) * 1992-05-12 2007-07-10 Richard C. Fuisz Rapidly dispersable compositions containing polydextrose
EP0641195B1 (de) * 1992-05-22 1996-04-10 Gödecke Aktiengesellschaft Verfahren zur herstellung retardierter arzneimittelzubereitungen
US5518730A (en) * 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
TW271400B (el) * 1992-07-30 1996-03-01 Pfizer
US5348758A (en) * 1992-10-20 1994-09-20 Fuisz Technologies Ltd. Controlled melting point matrix formed with admixtures of a shearform matrix material and an oleaginous material
US5380473A (en) * 1992-10-23 1995-01-10 Fuisz Technologies Ltd. Process for making shearform matrix
GB9224855D0 (en) * 1992-11-27 1993-01-13 Smithkline Beecham Plc Pharmaceutical compositions
US5569467A (en) 1993-05-15 1996-10-29 Societe De Conseils De Recherches Et D'applications (S.C.R.A.S.) Process for the preparation of microballs and microballs thus obtained
US5690959A (en) 1993-05-29 1997-11-25 Smithkline Beecham Corporation Pharmaceutical thermal infusion process
US5851553A (en) 1993-09-10 1998-12-22 Fuisz Technologies, Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5597416A (en) * 1993-10-07 1997-01-28 Fuisz Technologies Ltd. Method of making crystalline sugar and products resulting therefrom
US5935600A (en) * 1993-09-10 1999-08-10 Fuisz Technologies Ltd. Process for forming chewable quickly dispersing comestible unit and product therefrom
US5433951A (en) * 1993-10-13 1995-07-18 Bristol-Myers Squibb Company Sustained release formulation containing captopril and method
AT401871B (de) * 1994-01-28 1996-12-27 Gebro Broschek Gmbh Verfahren zur herstellung von s(+)-ibuprofen- partikeln mit verbesserten fliesseigenschaften und deren verwendung zur arzneimittelherstellung
GB9402203D0 (en) * 1994-02-04 1994-03-30 Smithkline Beecham Plc Pharmaceutical formulation
AU696855B2 (en) * 1994-03-18 1998-09-17 Shire Laboratories, Inc. Emulsified drug delivery systems
US5605889A (en) * 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
RU2130311C1 (ru) * 1994-05-06 1999-05-20 Пфайзер Инк. Лекарственные формы азитромицина с контролируемым высвобождением
DE19509807A1 (de) * 1995-03-21 1996-09-26 Basf Ag Verfahren zur Herstellung von Wirkstoffzubereitungen in Form einer festen Lösung des Wirkstoffs in einer Polymermatrix sowie mit diesem Verfahren hergestellte Wirkstoffzubereitungen
US5567439A (en) * 1994-06-14 1996-10-22 Fuisz Technologies Ltd. Delivery of controlled-release systems(s)
US5582855A (en) 1994-07-01 1996-12-10 Fuisz Technologies Ltd. Flash flow formed solloid delivery systems
US5556652A (en) * 1994-08-05 1996-09-17 Fuisz Technologies Ltd. Comestibles containing stabilized highly odorous flavor component delivery systems
US5601761A (en) * 1994-09-26 1997-02-11 The Dow Chemical Company Encapsulated active materials and method for preparing same
US5493044A (en) * 1994-10-20 1996-02-20 Fmc Corporation Process for preparing alkylsilyl or arylsilyl ethers
US6083430A (en) * 1994-10-28 2000-07-04 Fuisz Technologies Ltd. Method of preparing a dosage unit by direct tableting and product therefrom
US5965164A (en) 1994-10-28 1999-10-12 Fuisz Technologies Ltd. Recipient-dosage delivery system
US5683720A (en) 1994-10-28 1997-11-04 Fuisz Technologies Ltd. Liquiflash particles and method of making same
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
FR2732621B1 (fr) * 1995-04-10 1997-06-06 Rhone Poulenc Chimie Perles d'un produit presentant le phenomene de surfusion et leur procede d'obtention
JP3470198B2 (ja) 1995-05-02 2003-11-25 大正製薬株式会社 経口投与用組成物
US5747058A (en) * 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US5883103A (en) * 1995-06-07 1999-03-16 Shire Laboratories Inc. Oral acyclovir delivery
AU6403196A (en) * 1995-06-30 1997-02-05 Baylor University Polyester/carboxylic acid composite materials
EP0784933A3 (en) * 1995-10-16 1997-11-26 Leaf, Inc. Extended release of additives in comestible products
US5919489A (en) * 1995-11-01 1999-07-06 Abbott Laboratories Process for aqueous granulation of clarithromycin
US5705190A (en) * 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
US5916582A (en) * 1996-07-03 1999-06-29 Alza Corporation Aqueous formulations of peptides
DE19629753A1 (de) * 1996-07-23 1998-01-29 Basf Ag Verfahren zur Herstellung von festen Arzneiformen
US6139872A (en) 1996-08-14 2000-10-31 Henkel Corporation Method of producing a vitamin product
HRP970485A2 (en) * 1996-09-13 1998-08-31 Joerg Rosenberg Process for producing solid pharmaceutical forms
US8828432B2 (en) * 1996-10-28 2014-09-09 General Mills, Inc. Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles
DE19652257A1 (de) * 1996-12-16 1998-06-18 Lohmann Therapie Syst Lts Einzeln dosierte, bei Kontakt mit Flüssigkeit schnell zerfallende, wirkstoff- und insbesondere aromastoffhaltige, folienförmige Darreichnungsform
US5948407A (en) * 1997-03-19 1999-09-07 Shire Laboratories Inc. Oral induction of tolerance to parenterally administered non-autologous polypeptides
US6010718A (en) * 1997-04-11 2000-01-04 Abbott Laboratories Extended release formulations of erythromycin derivatives
US6551616B1 (en) * 1997-04-11 2003-04-22 Abbott Laboratories Extended release formulations of erythromycin derivatives
US6656508B2 (en) * 1997-04-17 2003-12-02 Amgen Inc. Sustained-release alginate gels
DE19729487A1 (de) * 1997-07-10 1999-01-14 Dresden Arzneimittel Verfahren zur Herstellung von Wirkstoff-Zubereitungen mit kontrollierter Freisetzung aus einer Matrix
SI9700186B (sl) * 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
US5851555A (en) 1997-08-15 1998-12-22 Fuisz Technologies Ltd. Controlled release dosage forms containing water soluble drugs
US5980941A (en) 1997-08-20 1999-11-09 Fuisz Technologies Ltd. Self-binding shearform compositions
US5840334A (en) 1997-08-20 1998-11-24 Fuisz Technologies Ltd. Self-binding shearform compositions
US5869098A (en) * 1997-08-20 1999-02-09 Fuisz Technologies Ltd. Fast-dissolving comestible units formed under high-speed/high-pressure conditions
IT1294760B1 (it) * 1997-09-03 1999-04-12 Jagotec Ag Procedimento per la preparazione di compresse farmaceutiche in grado di cedere,secondo schemi predeterminabili, principi attivi poco
ES2236943T3 (es) * 1997-09-19 2005-07-16 Shire Laboratories Inc. Perlas de disolucion solida.
US6013280A (en) * 1997-10-07 2000-01-11 Fuisz Technologies Ltd. Immediate release dosage forms containing microspheres
IE970731A1 (en) * 1997-10-07 2000-10-04 Fuisz Internat Ltd Product and method for the treatment of hyperlipidemia
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US5891845A (en) * 1997-11-21 1999-04-06 Fuisz Technologies Ltd. Drug delivery systems utilizing liquid crystal structures
DK1037634T3 (da) 1997-12-08 2005-12-19 Altana Pharma Ag Oral administrationsform som omfatter en protonpumpeinhibitor (fx pantoprazo)
US6270804B1 (en) * 1998-04-03 2001-08-07 Biovail Technologies Ltd. Sachet formulations
US6423345B2 (en) * 1998-04-30 2002-07-23 Acusphere, Inc. Matrices formed of polymer and hydrophobic compounds for use in drug delivery
JPH11335300A (ja) * 1998-05-20 1999-12-07 Sumitomo Pharmaceut Co Ltd グリセリン脂肪酸エステルを使用した徐放性製剤
FR2779651B1 (fr) * 1998-06-16 2001-04-20 Gattefosse Ets Sa Procede pour la fabrication de comprimes a liberation prolongee de principe(s) actif(s) presentant une cinetique de dissolution d'ordre zero
US6086920A (en) * 1998-08-12 2000-07-11 Fuisz Technologies Ltd. Disintegratable microspheres
US6117452A (en) * 1998-08-12 2000-09-12 Fuisz Technologies Ltd. Fatty ester combinations
CA2245398C (en) * 1998-08-21 2002-01-29 Apotex Inc. Azithromycin monohydrate isopropanol clathrate and methods for the manufacture thereof
US6165512A (en) 1998-10-30 2000-12-26 Fuisz Technologies Ltd. Dosage forms containing taste masked active agents
EP1484062A1 (en) * 1998-11-30 2004-12-08 Teva Pharmaceutical Industries Limited Crystalline azithromycin, process for manufacture and pharmaceutical compositions thereof
DE19901683B4 (de) * 1999-01-18 2005-07-21 Grünenthal GmbH Analgetikum mit kontrollierter Wirkstofffreisetzung
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
EP1027888B1 (en) * 1999-02-10 2009-06-10 Pfizer Products Inc. Osmotic system for delivery of solid amorphous dispersions of drugs
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6291013B1 (en) * 1999-05-03 2001-09-18 Southern Biosystems, Inc. Emulsion-based processes for making microparticles
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
EP1216026A1 (en) * 1999-09-27 2002-06-26 Sonus Pharmaceuticals, Inc. Compositions of tocol-soluble therapeutics
IL141438A0 (en) * 2000-02-23 2002-03-10 Pfizer Prod Inc Method of increasing the bioavailability and tissue penetration of azithromycin
AR030557A1 (es) * 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
PL371125A1 (en) * 2001-12-21 2005-06-13 Pfizer Products Inc. Methods for wet granulating azithromycin
WO2003053416A1 (en) * 2001-12-21 2003-07-03 Pfizer Products Inc. Directly compressible formulations of azithromycin
US6682759B2 (en) * 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
MXPA04007427A (es) * 2002-02-01 2004-10-11 Pfizer Prod Inc Formulaciones de azitromicina granuladas por via seca.
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
PL1648473T3 (pl) * 2003-07-24 2009-07-31 Pliva Hrvatska D O O Pojedyncza dawka szybko rozpuszczającej się azytromycyny

Also Published As

Publication number Publication date
JP2010132700A (ja) 2010-06-17
EA200401216A1 (ru) 2005-12-29
BRPI0403935B8 (pt) 2021-05-25
TW200518784A (en) 2005-06-16
DE602004016444D1 (de) 2008-10-23
UY28509A1 (es) 2005-07-29
BRPI0403935B1 (pt) 2018-02-06
KR100906290B1 (ko) 2009-07-06
DK1537859T3 (da) 2008-11-17
PT1537859E (pt) 2008-11-18
PL379984A1 (pl) 2006-11-27
US20050123627A1 (en) 2005-06-09
NZ535464A (en) 2009-03-31
EA010110B1 (ru) 2008-06-30
BRPI0403935A (pt) 2005-08-09
DOP2004000994A (es) 2005-06-30
EP1537859A3 (en) 2005-07-06
EP1537859B1 (en) 2008-09-10
PE20050573A1 (es) 2005-09-05
GEP20074056B (en) 2007-03-12
RS84704A (sr) 2007-02-05
CA2467611A1 (en) 2005-06-04
IS2672B (is) 2010-09-15
AR045630A1 (es) 2005-11-02
MA27848A1 (fr) 2006-04-03
US20060029677A1 (en) 2006-02-09
TWI351969B (en) 2011-11-11
OA12858A (en) 2006-09-15
CR7500A (es) 2007-09-03
IL164165A0 (en) 2005-12-18
NL1026315A1 (nl) 2005-06-07
US20080015343A1 (en) 2008-01-17
US20060039988A1 (en) 2006-02-23
KR20060033851A (ko) 2006-04-20
PL1537859T3 (pl) 2009-01-30
NO20043903L (no) 2004-11-09
PA8611501A1 (es) 2005-08-04
CL2004001501A1 (es) 2005-05-13
IL164165A (en) 2012-01-31
WO2005053650A8 (en) 2005-12-01
JP2005162733A (ja) 2005-06-23
SI1537859T1 (sl) 2008-12-31
JP4602711B2 (ja) 2010-12-22
US6984403B2 (en) 2006-01-10
NL1026315C2 (nl) 2006-01-24
EP1537859A2 (en) 2005-06-08
HRP20040865A2 (en) 2006-02-28
ATE407663T1 (de) 2008-09-15
ES2312929T3 (es) 2009-03-01
WO2005053650A1 (en) 2005-06-16
HK1080367B (zh) 2010-11-05
HK1080367A1 (en) 2006-04-28
MXPA04009424A (es) 2005-07-26
CA2467611C (en) 2010-03-30
IS7464A (is) 2005-06-05

Similar Documents

Publication Publication Date Title
CY1108486T1 (el) Μορφες δοσολογιας αζιθρομυκινης με μειωμενες παρενεργειες
CY1119865T1 (el) Φαρμακευτικες συνθεσεις για την αντιμετωπιση της νοσου του παρκινσον
CY1113051T1 (el) Ιατρικα παρασκευασματα για τη θεραπευτικη αγωγη της ανεπαρκειας της α-γαλακτοσιδασης α
CY1116075T1 (el) Νεες συνθεσεις λιποσωματων
CY1116103T1 (el) Υποκατεστημενα παραγωγα 1,2,3,4-τετραϋδροϊσοκινολινης
ATE452129T1 (de) N-phenyl-2-pyrimidine-amine derivatives
CY1112178T1 (el) Παραγωγα πιπεραζινης και χρηση αυτων ως θεραπευτικων παραγοντων
CY1107838T1 (el) Παραγωγα αδαμαντανιου για τη θεραπεια φλεγμονωδων, ανοσολογικων και καρδιαγγειακων ασθενειων
CY1111797T1 (el) Τοπικη φαρμακοτεχνικη μορφη ιβερμεκτινης για την θεραπεια δερματολογικων καταστασεων
CY1110332T1 (el) Παραγωγα βενζιμιδαζολης, συνθεσεις που τα περιεχουν, παρασκευη αυτων και χρηση τους
EA201000643A1 (ru) Замещенное производное этилендиамина для лечения микобактериальных заболеваний и фармацевтическая композиция на его основе
DE60143857D1 (de) Zusammensetzung bestehend aus phy906 und chemotherapeutika
PT1383752E (pt) 3-piperidinopropiofenonas deuteradas assim como farmacos contendo estes compostos
SE0401342D0 (sv) Therapeutic compounds
CY1106845T1 (el) Χρηση της φλουμαζενιλης για την παρασκευη ενος φαρμακου για την αγωγη της εξαρτησεως απο την κοκαϊνη
EE200200565A (et) Vaskulaarse kahjustava toimega kombinatsioonravi
EA200200922A1 (ru) Композиция, включающая камптотецин и производное пиримидина, для лечения рака
BR0112807A (pt) Derivados de indol e sua aplicação como medicamento
EP1379508A4 (en) N- (ARYL) -2-ARYLETHESULFONAMIDES AND THEIR THERAPEUTIC APPLICATIONS
DK1401405T3 (da) Orale, farmaceutiske sammensætninger med forbedret biotilgængelighed
CY1107231T1 (el) Υποκατεστημενα παραγωγα 4-αμινοκυκλοεξανολης
EA200700777A1 (ru) Содержащие октенидин таблетки для рассасывания, предназначенные для лечения воспалительных заболеваний полости рта и глотки
NO20031410L (no) Anvendelse av distamycinderivater for fremstilling av medikamenter
HN2001000038A (es) Sistema de administracion oral controlada para la ingestion diaria de ciprofloxacina
ECSP045351A (es) Formas de dosificación de azitromicina con efectos secundarios reducidos